AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT04673617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Study identification
- NCT ID
- NCT04673617
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- AB-101 Drug
- Rituximab Drug
- Interleukin-2 Drug
- Cyclophosphamide Drug
- Fludarabine Drug
- Bendamustine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2021
- Primary completion
- Oct 5, 2025
- Completion
- Oct 5, 2025
- Last update posted
- Apr 2, 2026
2021 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Artiva Clinical Trial Site | Birmingham | Alabama | 35249 | — |
| Artiva Clinical Trial Site | Tucson | Arizona | 85719 | — |
| Artiva Clinical Trial Site | Orange | California | 92868 | — |
| Artiva Clinical Trial Site | San Diego | California | 92093 | — |
| Artiva Clinical Trial Site | Gainesville | Florida | 32608 | — |
| Artiva Clinical Trial Site | Atlanta | Georgia | 30342 | — |
| Artiva Clinical Trial Site | Chicago | Illinois | 60612 | — |
| Artiva Clinical Trial Site | Iowa City | Iowa | 52242 | — |
| Artiva Clinical Trial Site | Wichita | Kansas | 67214 | — |
| Artiva Clinical Trial Site | Louisville | Kentucky | 40241 | — |
| Artiva Clinical Trial Site | Detroit | Michigan | 48201 | — |
| Artiva Clinical Trial Site | Lake Success | New York | 11042 | — |
| Artiva Clinical Trial Site | New York | New York | 11021 | — |
| Artiva Clinical Trial Site | Columbus | Ohio | 43214 | — |
| Artiva Clinical Trial Site | Portland | Oregon | 97239 | — |
| Artiva Clinical Trial Site | Philadelphia | Pennsylvania | 19107 | — |
| Artiva Clinical Trial Site | Philadelphia | Pennsylvania | 19111 | — |
| Artiva Clinical Trial Site | Providence | Rhode Island | 02903 | — |
| Artiva Clinical Trial Site | Dallas | Texas | 75246 | — |
| Artiva Clinical Trial Site | Salt Lake City | Utah | 84112 | — |
| Artiva Clinical Trial Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04673617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04673617 live on ClinicalTrials.gov.